André Scheen

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Luc F. Van Gaal, Aila Rissanen, André Scheen et al. · The Lancet · 2005 · 1.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

André Scheen, Nick Finer, Priscilla Hollander et al. · The Lancet · 2006 · 736 citations · Full text

Medicine, Endocrinology, Pharmacology +13

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

Ruud van Winkel, D Van Eyck, Linda Hanssens et al. · Schizophrenia Research · 2006 · 314 citations · Full text

Medicine, Pharmacology, Psychiatry +11